NKA Bio is developing new medicines to improve critical care. Our lead product is NKA01, a temperature-stable antibody for trauma patients. When you are severely injured, it is a race against time to get to surgery. The average person dies 8 minutes before lifesaving treatment can be delivered. But in the future, when minutes count, our antibody will buy hours. At NKA Bio, our treatment presses pause on death. With an injection of NKA01 by EMS, our drug could buy more time for transport and lifesaving surgery.
There is no investment information
No recent news or press coverage available for NKA Bio | Techstars '24.